Exhibit 99.1
MicroVision Announces Fourth Quarter and Full Year 2024 Results
REDMOND, WA / ACCESSWIRE / March 26, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its fourth quarter 2024 results.
Key Business Highlights
| ● | Significant momentum toward near-term revenue opportunities from multiple leading industrial companies in the autonomous mobile robot (AMR) and automated guided vehicle (AGV) sector. | |
| ● | Actively engaged with top-tier global automotive OEMs, with seven high-volume RFQs for passenger vehicles and custom development opportunities. | |
| ● | Secured production commitment to ensure continuous and uninterrupted supply of sensors and integrated software to meet anticipated volume demand. | |
| ● | Deepened executive leadership expertise with the hiring of Glen DeVos, former CTO of Aptiv, to lead the enhancement of our product portfolio and expansion of our customer solutions. | |
| ● | Streamlined cost structure in 2024, resulting in sequential improvement in cash burn. | |
| ● | Secured a $75 million convertible note facility with an institutional investor, plus raised an additional $8 million in the first quarter of 2025 through an equity sale to the same investor. |
“MicroVision is well positioned to secure revenue opportunities for 2025, primarily from three verticals: industrial, automotive, and defense,” said Sumit Sharma, MicroVision’s Chief Executive Officer. “Our unique value proposition continues to be our integrated perception software with our MAVIN and MOVIA sensors. We continue to offer compelling solutions to industrial customers and automotive OEMs at attractive price points.”
Sharma continued, “With a well-capitalized balance sheet including $75 million in cash and cash equivalents and access to additional capital of up to $161 million subject to certain conditions, we believe we are in a strong position to support customer demand and commit to high-volume deliveries. Last year, we secured a production commitment with ZF to enable us to fulfill demand in the range of $30-$50 million over the next 12-18 months, which we expect to be driven primarily by customers in the AMR/AGV vertical. With a strong balance sheet and improved cost structure, we are offering comprehensive solutions at competitive prices to solidify our position in the market. We expect to continue scaling resources, both internally and with third party vendors and suppliers, as we remain engaged with automotive OEMs and responsive to their evolving timelines.”
Key Financial Highlights for Q4 2024 and Full Year 2024
| ● | Revenue for the fourth quarter of 2024 was $1.7 million, compared to $5.1 million for the fourth quarter of 2023. Excluding the one-time revenue from Microsoft of $4.6 million in Q4 2023, the revenue growth in Q4 2024 was driven by demand primarily from industrial customers. Q4 revenue was short of our expectations as a customer was delayed into 2025. |
| ● | Net loss for the fourth quarter of 2024 was $31.2 million, or $0.14 per share, which includes $2.0 million of non-cash, share-based compensation expense and $13.2 million of the new convertible note-related expense, compared to a net loss of $19.7 million, or $0.10 per share, which includes $4.6 million of non-cash, share-based compensation expense, for the fourth quarter of 2023. | |
| ● | Adjusted EBITDA for the fourth quarter of 2024 was a $13.2 million loss, compared to a $13.6 million loss for the fourth quarter of 2023. | |
| ● | Cash used in operations in the fourth quarter of 2024 was $15.0 million, compared to cash used in operations in the fourth quarter of 2023 of $16.6 million. | |
| ● | The Company ended the fourth quarter of 2024 with $74.7 million in cash and cash equivalents, including investment securities, compared to $73.8 million at December 31, 2023. |
Subsequent to the fourth quarter, the Company bolstered its financial position by entering into an agreement to raise up to $17 million in new equity capital and reducing future cash obligations stemming from its $75 million senior secured convertible note facility with High Trail Capital. To date, $12.25 million of the convertible note has been converted into common stock, thereby reducing the Company’s obligations under the note by over 27%. With this new equity investment, the Company has access to $161 million of capital, subject to certain market conditions, including $17 million in new equity capital, $114 million under its existing ATM, or at-the-market, facility and $30 million from the remaining commitment pursuant to the convertible note facility.
Conference Call and Webcast: Q4 2024 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 1:30 PM PT/4:30 PM ET on Wednesday, March 26, 2025 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on March 26, 2025.
The live webcast and slide presentation can be accessed on the Company’s Investor Relations website under the Events tab HERE. The webcast will be archived on the website for future viewing.
About MicroVision
MicroVision drives global adoption of innovative perception solutions to make mobility and autonomy safer. Fueled by engineering excellence in Redmond, Washington and Hamburg, Germany, MicroVision develops and supplies an integrated solution built on its perception software stack, incorporating application software and processing data from differentiated sensor systems. MicroVision’s proprietary technology solutions deliver enhanced safety for a variety of industrial applications, including robotics, automated warehouse, and agriculture, and the automotive industry accelerating advanced driver-assistance systems (ADAS) and autonomous driving, as well as for military applications. With deep roots in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software, MicroVision has the expertise to deliver safe mobility at the speed of life.
For more information, visit the Company’s website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.
MicroVision, MAVIN, MOSAIK, and MOVIA are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision’s condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measures “adjusted EBITDA” and “adjusted Gross Profit.” Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; bargain purchase gain; gains and losses on derivatives and disposals; share-based compensation; impairment charges; and restructuring costs. Adjusted Gross Profit is calculated as GAAP gross profit before share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
MicroVision believes that the presentation of adjusted EBITDA and adjusted Gross Profit provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision’s past financial reports, and facilitates comparisons with other companies in the Company’s industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses these non-GAAP measures when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company’s operating results and facilitates comparisons of the Company’s core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA and adjusted Gross Profit are useful to investors in their assessment of MicroVision’s operating performance and the valuation of the Company.
Adjusted EBITDA and adjusted Gross Profit are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision’s business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measures should not be construed as an inference that these costs are unusual or infrequent.
The Company compensates for limitations of the adjusted EBITDA measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
Similarly for adjusted Gross Profit, the Company compensates for limitations of the measure by prominently disclosing GAAP gross profit which is the difference between Revenue and Cost of revenue, which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation by backing out share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
Forward-Looking Statements
Certain statements contained in this release, including customer engagement and the likelihood of success; opportunities for revenue and cash; expense reduction; market position; product portfolio; product and manufacturing capabilities; access to capital and capital-raising opportunities; and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements; its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
Investor Relations Contact
Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com
Media Contact
Marketing@MicroVision.com
Source: MicroVision, Inc.
MicroVision, Inc.
Consolidated Balance Sheets
(In thousands)
| December 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 54,486 | $ | 45,167 | ||||
| Investment securities, available-for-sale | 20,216 | 28,611 | ||||||
| Restricted cash, current | 261 | 3,263 | ||||||
| Accounts receivable, net of allowances | 926 | 949 | ||||||
| Inventory | 2,294 | 3,874 | ||||||
| Other current assets | 4,287 | 4,890 | ||||||
| Total current assets | 82,470 | 86,754 | ||||||
| Property and equipment, net | 7,061 | 9,032 | ||||||
| Operating lease right-of-use assets | 16,746 | 13,758 | ||||||
| Restricted cash, net of current portion | 1,500 | 961 | ||||||
| Intangible assets, net | 10,972 | 17,235 | ||||||
| Other assets | 2,412 | 1,895 | ||||||
| Total assets | $ | 121,161 | $ | 129,635 | ||||
| Liabilities and Shareholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,132 | $ | 2,271 | ||||
| Accrued liabilities | 2,542 | 8,640 | ||||||
| Accrued liability for Ibeo business combination | - | 6,300 | ||||||
| Contract liabilities | 308 | 300 | ||||||
| Derivative liability | 14,581 | - | ||||||
| Notes payable, current | 24,248 | - | ||||||
| Operating lease liabilities, current | 2,682 | 2,323 | ||||||
| Other current liabilities | 458 | 669 | ||||||
| Total current liabilities | 45,951 | 20,503 | ||||||
| Note payable, net of current portion | 8,754 | - | ||||||
| Operating lease liabilities, net of current portion | 15,954 | 12,714 | ||||||
| Other long-term liabilities | 1,733 | 614 | ||||||
| Total liabilities | 72,392 | 33,831 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ Equity | ||||||||
| Common stock at par value | 225 | 195 | ||||||
| Additional paid-in capital | 910,825 | 860,765 | ||||||
| Accumulated other comprehensive income | - | 210 | ||||||
| Accumulated deficit | (862,281 | ) | (765,366 | ) | ||||
| Total shareholders’ equity | 48,769 | 95,804 | ||||||
| Total liabilities and shareholders’ equity | $ | 121,161 | $ | 129,635 | ||||
MicroVision, Inc.
Consolidated Statements of Operations
(In thousands, except per share data)
Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 1,650 | $ | 5,101 | $ | 4,696 | $ | 7,259 | ||||||||
| Cost of revenue | 4,116 | 902 | 7,530 | 2,772 | ||||||||||||
| Gross (loss) profit | (2,466 | ) | 4,199 | (2,834 | ) | 4,487 | ||||||||||
| Research and development expense | 8,764 | 14,580 | 49,015 | 56,707 | ||||||||||||
| Sales, marketing, general and administrative expense | 5,923 | 9,517 | 29,346 | 36,689 | ||||||||||||
| Impairment loss on intangible assets | 1,154 | - | 4,181 | - | ||||||||||||
| Loss (gain) on disposal of fixed assets | 165 | (9 | ) | 143 | (34 | ) | ||||||||||
| Total operating expenses | 16,006 | 24,088 | 82,685 | 93,362 | ||||||||||||
| Loss from operations | (18,472 | ) | (19,889 | ) | (85,519 | ) | (88,875 | ) | ||||||||
| Bargain purchase gain, net of tax | - | (37 | ) | - | 1,669 | |||||||||||
| Interest expense | (4,424 | ) | (24 | ) | (4,457 | ) | (80 | ) | ||||||||
| Unrealized loss on derivative liability | (8,866 | ) | - | (8,866 | ) | - | ||||||||||
| Other income | 688 | 688 | 2,434 | 5,590 | ||||||||||||
| Net loss before taxes | $ | (31,074 | ) | $ | (19,262 | ) | $ | (96,408 | ) | $ | (81,696 | ) | ||||
| Income tax expense | (81 | ) | (475 | ) | (507 | ) | (1,146 | ) | ||||||||
| Net loss | $ | (31,155 | ) | $ | (19,737 | ) | $ | (96,915 | ) | $ | (82,842 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.14 | ) | $ | (0.10 | ) | $ | (0.46 | ) | $ | (0.45 | ) | ||||
| Weighted-average shares outstanding - basic and diluted | 219,475 | 190,649 | 209,510 | 182,802 | ||||||||||||
MicroVision, Inc.
Consolidated Statements of Cash Flows
(In thousands)
| Twelve months ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (96,915 | ) | $ | (82,842 | ) | ||
| Adjustments to reconcile net loss to net cash used in operations: | ||||||||
| Depreciation and amortization | 6,920 | 7,864 | ||||||
| Bargain purchase gain, net of tax | - | (1,669 | ) | |||||
| Loss (gain) on disposal of fixed assets | 143 | (34 | ) | |||||
| Unrealized loss on derivative liability | 8,866 | - | ||||||
| Impairment of intangible assets | 4,181 | - | ||||||
| Impairment of operating lease right-of-use assets | 405 | - | ||||||
| Impairment of property and equipment | - | 12 | ||||||
| Inventory write-downs | 2,045 | 76 | ||||||
| Amortization of debt discount and issuance costs on notes payable | 4,382 | - | ||||||
| Share-based compensation expense | 11,535 | 16,141 | ||||||
| Net accretion of premium on short-term investments | (951 | ) | (1,275 | ) | ||||
| Change in: | ||||||||
| Accounts receivable | 23 | (949 | ) | |||||
| Inventory | (495 | ) | (892 | ) | ||||
| Other current and non-current assets | 85 | (2,096 | ) | |||||
| Accounts payable | (1,139 | ) | 942 | |||||
| Accrued liabilities | (6,098 | ) | 6,571 | |||||
| Contract liabilities and other current liabilities | (188 | ) | (6,452 | ) | ||||
| Operating lease liabilities | (2,491 | ) | (2,500 | ) | ||||
| Other long-term liabilities | 1,152 | 13 | ||||||
| Net cash used in operating activities | (68,540 | ) | (67,090 | ) | ||||
| Cash flows from investing activities | ||||||||
| Sales of investment securities | 35,411 | 76,700 | ||||||
| Purchases of investment securities | (26,065 | ) | (41,710 | ) | ||||
| Cash paid for Ibeo business combination | (6,300 | ) | (11,233 | ) | ||||
| Purchases of property and equipment | (374 | ) | (1,935 | ) | ||||
| Net cash provided by investing activities | 2,672 | 21,822 | ||||||
| Cash flows from financing activities | ||||||||
| Principal payments under finance leases | - | (21 | ) | |||||
| Principal proceeds from notes payable, net of debt discount and issuance costs | 38,080 | - | ||||||
| Proceeds from stock option exercises | 62 | 175 | ||||||
| Net proceeds from issuance of common stock | 34,748 | 72,284 | ||||||
| Net cash provided by financing activities | 72,890 | 72,438 | ||||||
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (166 | ) | 267 | |||||
| Net increase in cash, cash equivalents, and restricted cash | 6,856 | 27,437 | ||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 49,391 | 21,954 | ||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 56,247 | $ | 49,391 | ||||
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of December 31, 2024 and 2023:
| December 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Cash and cash equivalents | $ | 54,486 | $ | 45,167 | ||||
| Restricted cash, current | 261 | 3,263 | ||||||
| Restricted cash, net of current portion | 1,500 | 961 | ||||||
| Cash, cash equivalents and restricted cash | $ | 56,247 | $ | 49,391 | ||||
MicroVision, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(In thousands)
Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Reconciliation of Non-GAAP Gross (Loss) Profit: | ||||||||||||||||
| Gross (loss) profit | $ | (2,466 | ) | $ | 4,199 | $ | (2,834 | ) | $ | 4,487 | ||||||
| Share-based compensation expense | - | - | - | - | ||||||||||||
| Amortization of acquired intangibles | 362 | 387 | 1,497 | 1,418 | ||||||||||||
| Adjusted Gross (Loss) Profit | $ | (2,104 | ) | $ | 4,586 | $ | (1,337 | ) | $ | 5,905 | ||||||
| Reconciliation of Non-GAAP Loss: | ||||||||||||||||
| GAAP Net loss | $ | (31,155 | ) | $ | (19,737 | ) | $ | (96,915 | ) | $ | (82,842 | ) | ||||
| Interest expense, net | 3,736 | (540 | ) | 2,023 | (2,119 | ) | ||||||||||
| Income taxes | 81 | 475 | 507 | 1,146 | ||||||||||||
| Depreciation and amortization | 1,674 | 1,576 | 6,920 | 7,864 | ||||||||||||
| Bargain purchase gain, net of tax | - | 37 | - | (1,669 | ) | |||||||||||
| Unrealized loss on derivative liability | 8,866 | - | 8,866 | - | ||||||||||||
| Share-based compensation expense | 2,013 | 4,635 | 11,535 | 16,141 | ||||||||||||
| Loss (gain) on disposal of fixed assets | 165 | - | 143 | - | ||||||||||||
| Impairment of operating lease right-of-use assets | (1 | ) | - | 405 | - | |||||||||||
| Impairment of intangible assets | 1,154 | - | 4,181 | - | ||||||||||||
| Restructuring costs | 241 | - | 6,047 | - | ||||||||||||
| Adjusted EBITDA | $ | (13,226 | ) | $ | (13,554 | ) | $ | (56,288 | ) | $ | (61,479 | ) | ||||